BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
See today's BioWorld
Home
» Interleukin Grows Portfolio Via Buyout, $30M Financing
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Interleukin Grows Portfolio Via Buyout, $30M Financing
Aug. 21, 2006
By
Jennifer Boggs
No Comments
In an effort to speed up progress on its genetic testing portfolio and its planned therapeutic work, Interleukin Genetics Inc. acquired consumer products firm Alan James Group LLC and secured $30 million in financing. (BioWorld Today)
BioWorld